The Newsroom

Investigations  /  04.23.2021

Investigation of Clover Health Investments

You Have Legal Options

Clover Health Investment, Corp.  (CLOV) Misled Shareholders Ahead of Going Public           

On October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company via a merger with Social Capital Hedosophia Holdings Corp. III (“SCH”).  SCH was a special purpose acquisition company (SPAC) that traded on the NYSE under IPOC.

On January 7, 2021, Clover and SCH announced it had completed the business combination and that shares of Clover would trade on NASDAQ under ticker symbol CLOV the next day.  On February 4, 2021, Hindenberg Research published a report revealing “how Clover Health and its Wall Street celebrity promoter, Chamath Palihapitiya, misled investors about critical aspects of Clover’s business in the run-up to the company’s SPAC go-public transaction last month.”  Notably, Hindenberg revealed that Clover’s business model and software offering “are under active investigation by the Department of Justice (DOJ), which is investigating at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals.”  On this news, shares of Clover dropped more than 12% from $13.95 on February 3, 2021, to $12.23 on February 4, 2021, representing a loss of $700 million in market capitalization.  The stock continued to tumble and now trades at just $8.50.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns